BioSpace News Archive

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended June 30, 2021, on Thursday, August 5, 2021, at 4:30 p.m. (ET).

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced that it has scheduled its second quarter 2021 financial results and corporate update for Thursday, August 5, 2021.

Atopic dermatitis is a chronic ailment that causes aggravation of the skin and results in red, irritated, swollen, and split skin.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, announced that it has entered into a collaboration with Oxford University in the United Kingdom to provide TPOXX® under an expanded access protocol to treat individuals affected by monkeypox in the Central African Republic.

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces that it has closed a follow-on financing of £4.24 million from its 2020 Seed round, bringing the total amount raised to £7.44m.

The life science company Sartorius Stedim Biotech acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany.

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the appointment of Uz Stammberger, MD, as Chief Medical Officer.

Daewoong Pharmaceutical announced its phase 2B clinical trial topline results for Foistar, which is being developed as a treatment for COVID-19.

Baylis Medical announced the first clinical use of the VersaCross® Large Access Solution.

West Pharmaceutical Services, Inc. announced its financial results for the second-quarter 2021 and updated full-year 2021 financial guidance.